Compare Incyte Corporation (INCY) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Kohl's Corporation — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Kohl's Corporation trades at $20.35 (market cap $2.28B). The key difference: Incyte Corporation is far larger — about 10× Kohl's Corporation's market cap, and Kohl's Corporation pays a 2.49% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Kohl's Corporation for 48 Days on average.
| INCY | KSS | |
|---|---|---|
Market Cap | $22.85B | $2.28B |
Volume | 1,927,029 | 4,960,280 |
Sector | Health | Consumer Cyclical |
52-Week High | $129.93 | $24.71 |
52-Week Low | $83.80 | $11.72 |
Typical Hold Time | 33 Days | 48 Days |
Enterprise Value | $18.35B | $7.88B |
Dividend Yield | — | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Kohl's (KSS) trades at $20.10, down 0.1% with a bullish technical signal supported by moving averages. The stock shows attractive valuation metrics with P/E of 8.63 and P/S of 0.15, while recent earnings beats and a new merchandising appointment signal operational improvements. Revenue trends show stabilization after several quarters of decline, with 2026 projections indicating potential margin recovery.
KSS presents a value opportunity with deep discount to sector peers, though persistent sales declines and competitive pressures remain headwinds. Analyst consensus is mixed with 30% buy ratings but a $15.50 price target below current levels, suggesting cautious optimism amid turnaround execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
